PI-103

製品コードS1038

PI-103化学構造

分子量(MW):348.36

PI-103は一種の多ターゲットPI3K阻害剤で、無細胞試験でp110α/β/δ/γに作用する時のIC50値は2 nM/3 nM/3 nM/15 nMです。PI-103はmTOR/DNA-PKに作用する効果が弱くて、このIC50値が30 nM/23 nMになります。

サイズ 価格(税別) 在庫  
JPY 22244.00 あり
JPY 24402.00 あり
JPY 44820.00 あり
JPY 61420.00 あり

カスタマーフィードバック(5)

  • (D) IGROV parental, shControl (two independent clones) and ShPKCiota (two independent clones) were treated with 5 μM GDC-0941 and 1.5 μM PI-103 for 24 hours and subjected to western blot analysis with the indicated antibodies. Each experiment was performed in triplicate.

    Oncogene, 2016, 35(19):2428-40. PI-103 purchased from Selleck.

    (A) MCF7 cells pre-treated with 100 nM siRNA for 72 h were re-seeded with normal growth media and grown overnight, then further transfected by 100nM of fresh siRNA. Twenty-(A) four hours after transfection, the cells were further treated with PI-103 for 24 h and the cell lysates were immunoblotted with the indicated antibodies. (B) Breast cancer cells carrying BRCA1 mutations were treated with 1 mM of PI-103 for 24h (left) or increasing amounts of PI-103 for 24 h (right). Cell lysates were analyzed by Western blotting with the indicated antibodies.

    Mol Carcinog 2012 52, 667-75 . PI-103 purchased from Selleck.

  • Knockdown of BRCA1 sensitizes cells to PI3K/AKT pathway inhibitors. MCF7 cells transfected with either BRCA1-siRNA or control-siRNA were treated with increasing amounts of inhibitors targeting the PI3K/AKT pathway for 48 h in triplicate. Viable cells were measured by MTT assay.

    Mol Carcinog 2012 ahead of print. PI-103 purchased from Selleck.

    Breast cancer cells were pretreated with 100ng/ml EGF for 15 min and then treated with the indicated concentrations of PI-103 for 24 hours.

     

     

    Dr. Zhang of Tianjin Medical University. PI-103 purchased from Selleck.

  • We treated all of drugs in T47D which has a PI3KCA H1044R mutation with the concentration shown below for 1 hour and performed western blot analysis using antibodies to phospho-AKT(SERINE 472), and total AKT.

     

     

    Saraswati Sukumar of Johns Hopkins University School of Medicine PI-103 purchased from Selleck.

製品安全説明書

PI3K阻害剤の選択性比較

生物活性

製品説明 PI-103は一種の多ターゲットPI3K阻害剤で、無細胞試験でp110α/β/δ/γに作用する時のIC50値は2 nM/3 nM/3 nM/15 nMです。PI-103はmTOR/DNA-PKに作用する効果が弱くて、このIC50値が30 nM/23 nMになります。
特性 The first potent, synthetic mTOR inhibitor.
ターゲット
p110α [3]
(Cell-free assay)
p110β [3]
(Cell-free assay)
p110δ [3]
(Cell-free assay)
p110γ [3]
(Cell-free assay)
DNA-PK [3]
(Cell-free assay)
2 nM 3 nM 3 nM 15 nM 23 nM
体外試験

PI-103 potently inhibits both the rapamycin-sensitive (mTORC1) and rapamycin-insensitive (mTORC2) complexes of the protein kinase mTOR. [1] PI-103 inhibits constitutive and growth factor-induced PI3K/Akt, as well as mTORC1 activation. [2] In blast cells, PI-103 inhibits leukemic proliferation, the clonogenicity of leukemic progenitors and induces mitochondrial apoptosis, especially in the compartment containing leukemic stem cells. PI-103 inhibits p110α >200-fold more potently than p110β. PI-103 also potently blocks production of PI(3,4)P2 and PIP3 in adipocytes and PIP3 in myotubes. [2] PI-103 inhibits phosphorylation of Akt with an IC95 100-fold lower than that for LY294002. Strikingly, PI-103 completely protects animals from insulin-stimulated decline in blood glucose. PI-103 has additive proapoptotic effects with etoposide in blast cells and in immature leukemic cells. [2]

細胞データ
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
SK-N-BE MYPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Ml\XNE05KM7:TR?= M2j6NFI1NzR6L{eyJIg> MYXpcoR2[2W|IITpcYUuKGGwZDDjc45k\W62cnH0bY9vNWSncHXu[IVvfCCrbnjpZol1cW:wIH;uJG5DKGOnbHyg[5Jwf3Sq NVfQUWZQOjZ{MkS2PFE>
SH-SY5Y MWXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NV7jfmFROC16IN88US=> M1WzclI1NzR6L{eyJIg> NGLnc45qdmS3Y3XzJJRqdWVvIHHu[EBkd26lZX70doF1cW:wLXTldIVv\GWwdDDpcohq[mm2aX;uJI9vKE6EIHPlcIwh\3Kxd4To NHW4OoYzPjJ{NE[4NS=>
SH-SY5Y  MYnBdI9xfG:|aYOgRZN{[Xl? MVixJO69VQ>? M37kW|AvPS1{NDDo MkLSd4Vve2m2aYrld{Bv\XW{b3LsZZN1d22jIHPlcIx{KHSxIHTvfI9zfWKrY3nuMYlv\HWlZXSgZZBweHSxc3nz Ml:3NlYzOjR4OEG=
G 35 SC NInXSlNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MWqwMlA2NTJyIN88US=> NIrIPIkzPC95MjDo M1LZdWROW09? MmLWbY5pcWKrdIOgZ4VtdCC4aXHibYxqfHliZH;z[UBidmRidHnt[UBl\XCnbnTlcpRtgQ>? NGXvOoIzPjF{MUK1NS=>
G 38 SC MV\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mk[yNE4xPS1{MDFOwG0> MnHLNlQwPzJiaB?= M1L5V2ROW09? NHmwOYxqdmirYnn0d{Bk\WyuII\pZYJqdGm2eTDkc5NmKGGwZDD0bY1mKGSncHXu[IVvfGy7 M1PtVlI3OTJzMkWx
G 40 SC NH3zTWZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHvwd4oxNjB3LUKwJO69VQ>? NFv2UXAzPC95MjDo NYrnTlFpTE2VTx?= NX3CPXI3cW6qaXLpeJMh[2WubDD2bYFjcWyrdImg[I9{\SCjbnSgeIlu\SCmZYDlcoRmdnSueR?= NHzZXoczPjF{MUK1NS=>
G 35 DC NYm1epBQT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NWfKOYxuOC5yNT2yNEDPxE1? MYOyOE84OiCq NEXPW3VFVVOR NXv6ZWNFcW6qaXLpeJMh[2WubDD2bYFjcWyrdImg[I9{\SCjbnSgeIlu\SCmZYDlcoRmdnSueR?= MkThNlYyOjF{NUG=
G 38 DC M3HoTmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MoLKNE4xPS1{MDFOwG0> MXGyOE84OiCq MVrEUXNQ M4[zXIlvcGmkaYTzJINmdGxidnnhZoltcXS7IHTvd4Uh[W6mIITpcYUh\GWyZX7k[Y51dHl? M3PwNlI3OTJzMkWx
G 40 DC NH[1dJVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3TzcVAvODVvMkCg{txO MVmyOE84OiCq NWTUeHVVTE2VTx?= NUTk[otscW6qaXLpeJMh[2WubDD2bYFjcWyrdImg[I9{\SCjbnSgeIlu\SCmZYDlcoRmdnSueR?= NVj4ZmlKOjZzMkGyOVE>
RD MX3BdI9xfG:|aYOgRZN{[Xl? MVGxM|EvPS9{IN88US=> MUO3NkBp NIfpfIdqdmS3Y3XzJIFxd3C2b4Ppd{Bkd22kaX7l[EB4cXSqIFfBUnQ3OQ>? NIDyRnYzPTd2OUO3PC=>
TE381.T NWLtc5NYSXCxcITvd4l{KEG|c3H5 MXmxM|EvPS9{IN88US=> NV\0Rnl[PzJiaB?= MknubY5lfWOnczDhdI9xfG:|aYOgZ49u[mmwZXSge4l1cCCJQV7UOlE> M2C5PVI2PzR7M{e4
RMS13 Mlu3RZBweHSxc3nzJGF{e2G7 NWL1[5F5OS9zLkWvNkDPxE1? M4CydFczKGh? MmnGbY5lfWOnczDhdI9xfG:|aYOgZ49u[mmwZXSge4l1cCCJQV7UOlE> NF3aOG0zPTd2OUO3PC=>
RH30  M4PscmFxd3C2b4Ppd{BCe3OjeR?= MXKxM|EvPS9{IN88US=> MVW3NkBp NUjPO3pJcW6mdXPld{BieG:ydH;zbZMh[2:vYnnu[YQhf2m2aDDHRW5VPjF? NUHXRnRwOjV5NEmzO|g>
VJ MmXVRZBweHSxc3nzJGF{e2G7 NGGyeHIyNzFwNT:yJO69VQ>? Mm\vO|IhcA>? M4XuPYlv\HWlZYOgZZBweHSxc3nzJINwdWKrbnXkJJdqfGhiR1HOWFYy MVGyOVc1QTN5OB?=
HS578T MVnD[YxtKF[rYXLpcIl1gSCDc4PhfS=> MkPvNE0{KM7:TR?= Mnr4O|IhcA>? MXvpcohq[mm2czDj[YxtKH[rYXLpcIl1gSCmb4PlJIRmeGWwZHXueIx6 MljmNlU4OjF2MUm=
BT549 NETHNIlE\WyuIG\pZYJqdGm2eTDBd5NigQ>? M4HwTlAuOyEQvF2= NHTxWGk4OiCq NXjUUoRqcW6qaXLpeJMh[2WubDD2bYFjcWyrdImg[I9{\SCmZYDlcoRmdnSueR?= NFXsb5kzPTd{MUSxPS=>
MDA-MB-231 MkfrR4VtdCCYaXHibYxqfHliQYPzZZk> M4fJbFAuOyEQvF2= MWG3NkBp MlXpbY5pcWKrdIOgZ4VtdCC4aXHibYxqfHliZH;z[UBl\XCnbnTlcpRtgQ>? M1LKRVI2PzJzNEG5
MDA-MB-468 M{[2bGNmdGxiVnnhZoltcXS7IFHzd4F6 NYfwVnFiOC1|IN88US=> M4X0R|czKGh? MYrpcohq[mm2czDj[YxtKH[rYXLpcIl1gSCmb4PlJIRmeGWwZHXueIx6 MkLsNlU4OjF2MUm=
MDA-MB-436 M3zsRWNmdGxiVnnhZoltcXS7IFHzd4F6 Mme4NE0{KM7:TR?= M3TDdlczKGh? NXTEcFBYcW6qaXLpeJMh[2WubDD2bYFjcWyrdImg[I9{\SCmZYDlcoRmdnSueR?= MWCyOVczOTRzOR?=
SUM149PT NIWzbI1E\WyuIG\pZYJqdGm2eTDBd5NigQ>? NY\OcoJROC1|IN88US=> MYW3NkBp NWTUXFM1cW6qaXLpeJMh[2WubDD2bYFjcWyrdImg[I9{\SCmZYDlcoRmdnSueR?= M3i4ZVI2PzJzNEG5
MDA-MB-468 M3nSXWZ2dmO2aX;uJGF{e2G7 M2jLR|AvODFvMUCg{txO MnzWNlQhcA>? NVPGOIFv\G:5boLl[5Vt[XSnczD0bIUhdGW4ZXzzJI9nKM7{LWTyR3AyNCClLV35Z{BidmRiY4njcIlvKEVicILveIVqdnQEoB?= MV2yOVczOTRzOR?=
MDA-MB-231 MUHGeY5kfGmxbjDBd5NigQ>? NHqwb3YxNjBzLUGwJO69VQ>? MVKyOEBp NFLuNGtld3ewcnXneYxifGW|IITo[UBt\X[nbIOgc4Yh|rJvVILDVFEtKGNvTYnjJIFv\CCleXPsbY4hTSCycn;0[Ylve8Li NF;6TlgzPTd{MUSxPS=>
HS578T NH2yUHpHfW6ldHnvckBCe3OjeR?= NWHpcYJrOC5yMT2xNEDPxE1? M2\RbFI1KGh? MXjkc5dvemWpdXzheIV{KHSqZTDs[ZZmdHNib3[g{tIuXHKFUEGsJIMuVXmlIHHu[EBkgWOuaX6gSUBxem:2ZXnud:Kh Mk\TNlU4OjF2MUm=
SW872 NXTTPZp7TnWwY4Tpc44hSXO|YYm= MYqwMlAyNTBwNTFOwG0> NEm0TI8zPCCq Mn\xdoVlfWOnczDBT3QheGixc4Doc5J6dGG2aX;uJEhxSUuWKTDhcoQhPEWEUEGgdIhwe3Cqb4L5cIF1cW:wIDjwOGVDWDFrIHnuJIEh\G:|ZT3k[ZBmdmSnboSgcYFvdmW{wrC= NYLZWnBLOjR4OUW2N|I>
SW982 MkDHSpVv[3Srb36gRZN{[Xl? MV2wMlAyNTBwNTFOwG0> NUeyUY5bOjRiaB?= MV3y[YR2[2W|IFHLWEBxcG:|cHjvdplt[XSrb36gLJBCU1RrIHHu[EA1TUKSMTDwbI9{eGixconsZZRqd25iKIC0SWJROSliaX6gZUBld3OnLXTldIVv\GWwdDDtZY5v\XMEoB?= NVvLb44{OjR4OUW2N|I>
SW872 NEO5dotCeG:ydH;zbZMhSXO|YYm= NH[1SYUxNjBzLUCuOUDPxE1? MnraOFghcA>? NWf6dXpXcW6mdXPld{BieG:ydH;zbZMh\G:|ZTDk[ZBmdmSnboTsfS=> Mk\INlQ3QTV4M{K=
SW982 NWnkOlVzSXCxcITvd4l{KEG|c3H5 M{TCXVAvODFvMD61JO69VQ>? M17aUlQ5KGh? NH3GbJJqdmS3Y3XzJIFxd3C2b4Ppd{Bld3OnIHTldIVv\GWwdHz5 MlLBNlQ3QTV4M{K=
AGS HG NWTyU5VYT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mny5TWM2OD1yLk[4JOKyKDBwMEOxJO69VQ>? NYD0eYRmOjR3OUe0O|g>
AGS LG Mnu4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFLRWZpKSzVyPUCuNFUhyrFiMD6wNFEh|ryP NF3tc|gzPDV7N{S3PC=>
HGC27 HG MkfmS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MoHvTWM2OD1yLkO4JOKyKDBwMEKyJO69VQ>? NYLwZ2l2OjR3OUe0O|g>
HGC27 LG M1e3dmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NUH6TIJQUUN3ME2wMlAzKMLzIECuNFA1KM7:TR?= M3XqVVI1PTl5NEe4
MKN45 HG M{PGW2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mn60TWM2OD1zLkCxJOKyKDBwMEWxJO69VQ>? M2PDcVI1PTl5NEe4
MKN45 LG MmHMS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MULJR|UxRTBwOEegxtEhOC5yM{Cg{txO NYjMNldxOjR3OUe0O|g>
NUGC4 HG M3PNcGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1\Xe2lEPTB;MUSuNEDDuSB|LkmxN{DPxE1? Mn7iNlQ2QTd2N{i=
NUGC4 LG MXTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NWfJW5ZqUUN3ME2xOE4xKMLzIEWuN|IyKM7:TR?= NV7vWlFROjR3OUe0O|g>
A549 NWnRR5FqTnWwY4Tpc44hSXO|YYm= NUnGeWNOOC5{NT:wMlUwOSEQvF2= MYCyOEBp NYfZUpZNcW6qaXLpeJMhSWu2IIDoc5NxcG:{eXzheIlwdiC|bHnnbJRtgQ>? M1rZWVI1OzVzNEK1
H460 M3vDUmZ2dmO2aX;uJGF{e2G7 Ml3GNE4zPS9yLkWvNUDPxE1? M3\Wd|I1KGh? MnHFbY5pcWKrdIOgRYt1KHCqb4PwbI9zgWyjdHnvckB{dGmpaITsfS=> MYqyOFM2OTR{NR?=
H661 MWjGeY5kfGmxbjDBd5NigQ>? NYnoXGQ1OC5{NT:wMlUwOSEQvF2= Mnr1NlQhcA>? M{GzR4lvcGmkaYTzJGFsfCCyaH;zdIhwenmuYYTpc44he2mpbnnmbYNidnSueR?= MknRNlQ{PTF2MkW=
SAS MULGeY5kfGmxbjDBd5NigQ>? NGTrZnoxNjJ3L{CuOU8yKM7:TR?= MUKyOEBp M4HjWolvcGmkaYTzJGFsfCCyaH;zdIhwenmuYYTpc44he2mpbnnmbYNidnSueR?= MUSyOFM2OTR{NR?=
UT5 M2PocmZ2dmO2aX;uJGF{e2G7 M1vpT|AvOjVxMD61M|Eh|ryP NVu2cXRyOjRiaB?= MYnpcohq[mm2czDBb5QheGixc4Doc5J6dGG2aX;uJJNq\26rZnnjZY51dHl? M4W5PFI1OzVzNEK1
FaDu MoTsSpVv[3Srb36gRZN{[Xl? NUjVe5Q{OC5{NT:wMlUwOSEQvF2= MYKyOEBp NFuzco5qdmirYnn0d{BCc3RicHjvd5Bpd3K7bHH0bY9vKHOrZ37p[olk[W62bIm= NXXFeVlOOjR|NUG0NlU>
RD M4DtTWFxd3C2b4Ppd{BCe3OjeR?= NGj5eXUyNzFwNT:yJO69VQ>? MnywO|IhcA>? NEPCTItFVVOR NHL0NXpqdmS3Y3XzJINie3Cjc3Wt[IVx\W6mZX70JIFxd3C2b4Ppd{Bkd22kaX7l[EB4cXSqIGXPNVI3 MlzvNlM3QDR7MkW=
TE671 MYHBdI9xfG:|aYOgRZN{[Xl? NEf2VXUyNzFwNT:yJO69VQ>? MVW3NkBp NHr0XnNFVVOR NX;IbXJJcW6mdXPld{Bk[XOyYYPlMYRmeGWwZHXueEBieG:ydH;zbZMh[2:vYnnu[YQhf2m2aDDVU|EzPg>? NEm3XoszOzZ6NEmyOS=>
RH30  NGq0e|lCeG:ydH;zbZMhSXO|YYm= NYqyUHplOS9zLkWvNkDPxE1? NVjwTnZZPzJiaB?= NIfxflNFVVOR NFjRWJBqdmS3Y3XzJINie3Cjc3Wt[IVx\W6mZX70JIFxd3C2b4Ppd{Bkd22kaX7l[EB4cXSqIGXPNVI3 MXSyN|Y5PDl{NR?=
RMS13 MlviRZBweHSxc3nzJGF{e2G7 MljNNU8yNjVxMjFOwG0> MoLaO|IhcA>? NVPPUXJUTE2VTx?= M1TEb4lv\HWlZYOgZ4F{eGG|ZT3k[ZBmdmSnboSgZZBweHSxc3nzJINwdWKrbnXkJJdqfGhiVV:xNlY> NXTYNFI3OjN4OES5NlU>
SUM149PT NU[wVFhjS2WubDDWbYFjcWyrdImgRZN{[Xl? MXewMlMh|ryP Ml\uO|IhcA>? MYjlcohidmOnczDjfZRwfG:6aXOg[YZn\WO2czDv[kBRUTONL1HLWEBx[XSqd3H5JIlvcGmkaYTvdpM> NXHoOpJTOjN4MEGwO|Q>
MDA-MB-468 MlLFR4VtdCCYaXHibYxqfHliQYPzZZk> M1fHfVAvOyEQvF2= MoOyO|IhcA>? NYLpc4tq\W6qYX7j[ZMh[3m2b4TvfIlkKGWoZnXjeJMhd2ZiUFmzT{9CU1RicHH0bJdigSCrbnjpZol1d3K| NUHqUINxOjN4MEGwO|Q>
MDA-MB-231 M1\rXWNmdGxiVnnhZoltcXS7IFHzd4F6 Ml7XNE4{KM7:TR?= MVy3NkBp MXjlcohidmOnczDjfZRwfG:6aXOg[YZn\WO2czDv[kBRUTONL1HLWEBx[XSqd3H5JIlvcGmkaYTvdpM> NF\N[ZkzOzZyMUC3OC=>
SY5Y NXfhVIVuTnWwY4Tpc44hSXO|YYm= NFfpSmkyNjVxMj61M|Uh|ryP NE\3XIYzPCCq MVjpcoR2[2W|IFexxsBk\WyuLXP5Z4xmKGG{cnXzeEBidmRiYYDvdJRwe2m| MX[yN|M4QDN2MR?=
SKNBE(2c) NIXxVFhHfW6ldHnvckBCe3OjeR?= MWOxMlUwOi53L{Wg{txO M2XvflI1KGh? NWO2d5Q4cW6mdXPld{BIOcLiY3XscE1kgWOuZTDhdpJme3RiYX7kJIFxd3C2b4Ppdy=> NV;ofJlEOjN|N{izOFE>
RD MnTURZBweHSxc3nzJGF{e2G7 NHjIWGI{KML3TR?= NIe2VI0yOiCq MW\EUXNQ NGHuTHd{\W6|aYTpfoV{KFKGIHPlcIx{KHSxIFTPXE1qdmS3Y3XkJIFxd3C2b4Ppdy=> NGThUIszOzNyMEiwPS=>
TP5014 M37GbGFxd3C2b4Ppd{BCe3OjeR?= NHPRcGc{KML3TR?= MkLmNVIhcA>? NYTreXc1TE2VTx?= NIO5do5{\W6|aYTpfoV{KFKGIHPlcIx{KHSxIFTPXE1qdmS3Y3XkJIFxd3C2b4Ppdy=> MmT5NlM{ODB6MEm=
HT1080 NYrvWGx5SXCxcITvd4l{KEG|c3H5 NGPIXZQ{KML3TR?= NVrrc|JwOTJiaB?= NWLJSJVITE2VTx?= NVz0Soxve2Wwc3n0bZpmeyCURDDj[YxteyC2bzDEU3gucW6mdXPl[EBieG:ydH;zbZM> M2XXTFI{OzByOEC5
A549 NUnTUWE4TnWwY4Tpc44hSXO|YYm= M2XYNlAuOy5|IN88US=> MX[3NkBp NVzrbotqcW6mdXPld{Bkd22ybHX0[UBld3ewcnXneYxifGmxbjDv[kBxSUuW NEjmdW4zOzJ3OUW5NS=>
HCC827 NWW1ZZM{TnWwY4Tpc44hSXO|YYm= NHzIeFMxNTNwMzFOwG0> M{LtOVczKGh? M1TuW4lv\HWlZYOgZ49ueGyndHWg[I94dnKnZ4XsZZRqd25ib3[gdGFMXA>? Ml70NlMzPTl3OUG=
H3122 NI\Jc3NHfW6ldHnvckBCe3OjeR?= M3PY[FAuOy5|IN88US=> M1XkcFczKGh? MVjpcoR2[2W|IHPvcZBt\XSnIHTve45z\We3bHH0bY9vKG:oIIDBT3Q> NX30dGJxOjN{NUm1PVE>
TALL-1 NHXGTVFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXP4PIN1OeLCid88US=> NIjJRWE4KGR? MX;k[YNz\WG|ZYOgeIhmKGOnbHygcpVu[mW{IIPp[45q\mmlYX70cJk> NGO4W2kzOzB|OEK3Ny=>
HPB-ALL MmGzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MWCx5qCK|ryP NUnyZWE6PyCm NFf6XVhl\WO{ZXHz[ZMhfGinIHPlcIwhdnWvYnXyJJNq\26rZnnjZY51dHl? NYHV[I5FOjNyM{iyO|M>
DND41 MXHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVq3[|l5OeLCid88US=> NUHiZpR6PyCm NFXMZ2tl\WO{ZXHz[ZMhfGinIHPlcIwhdnWvYnXyJJNq\26rZnnjZY51dHl? NEjQU5QzOzB|OEK3Ny=>
SUP-T1 NYfJeXNtT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3rJV|HjiIoQvF2= Mof2O{Bl MVHk[YNz\WG|ZYOgeIhmKGOnbHygcpVu[mW{IIPp[45q\mmlYX70cJk> MYOyN|A{QDJ5Mx?=
PEER MlXZS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NUXoNmRpOeLCid88US=> NXzoT3NUPyCm MVfk[YNz\WG|ZYOgeIhmKGOnbHygcpVu[mW{IIPp[45q\mmlYX70cJk> M17tUVI{ODN6Mkez
ALL-SIL NV6wcpJpT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MnzlNgKBkc7:TR?= NHnCb|I4KGR? MX;k[YNz\WG|ZYOgeIhmKGOnbHygcpVu[mW{IIPp[45q\mmlYX70cJk> NUnpNm95OjNyM{iyO|M>
KE37 MVfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MV:x5qCK|ryP NGLPVXQ4KGR? Mn7H[IVkemWjc3XzJJRp\SClZXzsJI52dWKncjDzbYdvcW[rY3HueIx6 NHrpZoQzOzB|OEK3Ny=>
Karpas-45 MWHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Ml3RNgKBkc7:TR?= MmnXO{Bl MlSw[IVkemWjc3XzJJRp\SClZXzsJI52dWKncjDzbYdvcW[rY3HueIx6 MVKyN|A{QDJ5Mx?=
RPMI-8402 NWL0NYJlT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MlzlNgKBkc7:TR?= MUC3JIQ> NGO1PI5l\WO{ZXHz[ZMhfGinIHPlcIwhdnWvYnXyJJNq\26rZnnjZY51dHl? MlfyNlMxOzh{N{O=
Jurkat NETJRWVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4K2dVHjiIoQvF2= NHKxNYo4KGR? NIj2SVdl\WO{ZXHz[ZMhfGinIHPlcIwhdnWvYnXyJJNq\26rZnnjZY51dHl? NXHMbHVFOjNyM{iyO|M>
MOLT-4 M3nPWWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXKx5qCK|ryP MXi3JIQ> NEjMZ4Nl\WO{ZXHz[ZMhfGinIHPlcIwhdnWvYnXyJJNq\26rZnnjZY51dHl? M2PXcVI{ODN6Mkez
PF-382 NX3uT|Z2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NIXDdYIy6oDLzszN NE\kNJU4KGR? MV\k[YNz\WG|ZYOgeIhmKGOnbHygcpVu[mW{IIPp[45q\mmlYX70cJk> NITyVGgzOzB|OEK3Ny=>
CCRF-CEM NYrEc3dGT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M{\Ed|HjiIoQvF2= NIrwelQ4KGR? NVTPblFC\GWlcnXhd4V{KHSqZTDj[YxtKG63bXLldkB{cWewaX\pZ4FvfGy7 MljhNlMxOzh{N{O=
LOUCY M{Czb2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4\VXFHjiIoQvF2= MVi3JIQ> M1PoToRm[3KnYYPld{B1cGViY3XscEBvfW2kZYKgd4lodmmoaXPhcpRtgQ>? M3XTdlI{ODN6Mkez
MOLT-16 NIDxNlNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXryXFB5OeLCid88US=> NXvnfIZoPyCm M4fuWYRm[3KnYYPld{B1cGViY3XscEBvfW2kZYKgd4lodmmoaXPhcpRtgQ>? MmH2NlMxOzh{N{O=
MM1S NGDMcGZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1fUdVAuOiEQvF2= Mmf5NlQhcA>? NUG5dWtYUUN3ME2wMlUh|ryP NEDIepUzOjh{OUKzOC=>
NCI-H929 NVPlRY42T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MV2wMVIh|ryP MkL0NlQhcA>? MXrJR|UxRTBwMkWg{txO M4njOlIzQDJ7MkO0
KMS12-BM  NFjYNItIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MojkNE0zKM7:TR?= MknXNlQhcA>? Mmf5TWM2OO,:nkKg{txO NIjJWFMzOjh{OUKzOC=>
MDA-MB-436 NX7CbVZUTnWwY4Tpc44hSXO|YYm= NYPuTYRoOSEQvF2= Mn74NlQhcA>? MXfy[YR2[2W|IITo[UBxcG:|cHjvdplt[XSrb36gc4YhSUuW MX2yNlQ5QDV7MB?=
SUM149PT MnLkSpVv[3Srb36gRZN{[Xl? MYKxJO69VQ>? M173[|I1KGh? MkfVdoVlfWOnczD0bIUheGixc4Doc5J6dGG2aX;uJI9nKEGNVB?= MlvLNlI1QDh3OUC=
SUM1315MO2 M2jITGZ2dmO2aX;uJGF{e2G7 NVyxRY1SOSEQvF2= M{PmRlI1KGh? MWTy[YR2[2W|IITo[UBxcG:|cHjvdplt[XSrb36gc4YhSUuW NHLvRVAzOjR6OEW5NC=>
HCC1937 NEeyWHVHfW6ldHnvckBCe3OjeR?= NX;RUVNVOSEQvF2= Ml\INlQhcA>? M4XuVpJm\HWlZYOgeIhmKHCqb4PwbI9zgWyjdHnvckBw\iCDS2S= NFuyPYEzOjR6OEW5NC=>
HCC827 NYDENHRjT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3OxNVAuOyEQvF2= M1:5TFczKGh? MXzJR|UxRTBwMzFOwG0> M1fZUlIyOjJyNEe0
PC-9  M4fE[mdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYjDO2NYOC1|IN88US=> M2LzVFczKGh? Mo\yTWM2OD1yLkig{txO M1\hcFIyOjJyNEe0
LN229 NUS0UFZjTnWwY4Tpc44hSXO|YYm= NIL0TVEyKM7:TR?= MlLuOFghcA>? MXfpcoR2[2W|IHH1eI9xcGGpb4PvcYUh\m:{bXH0bY9v MnXtNlExPjJ7OUO=
U87 M2HjTWZ2dmO2aX;uJGF{e2G7 M1n3WlEh|ryP MXO0PEBp MlXxbY5lfWOnczDheZRweGijZ3;zc41mKG[xcn3heIlwdg>? MmXhNlExPjJ7OUO=
U373 Mnf5SpVv[3Srb36gRZN{[Xl? NWDGVXdvOSEQvF2= MXu0PEBp MmPkbY5lfWOnczDheZRweGijZ3;zc41mKG[xcn3heIlwdg>? Mmf4NlExPjJ7OUO=
SF767 NFTwPXdHfW6ldHnvckBCe3OjeR?= MWCxJO69VQ>? M3foeFQ5KGh? NVzpTZhicW6mdXPld{BifXSxcHjh[49{d22nIH\vdo1ifGmxbh?= MlvCNlExPjJ7OUO=
Mel-Juso MYLD[YxtKF[rYXLpcIl1gSCDc4PhfS=> MkDpNE4xOeLCk{Gw5qCK|ryP NV;xeWo4PzJiaB?= MWHpcohq[mm2czDj[YxtKH[rYXLpcIl1gSCmb4PlJIRmeGWwZHXueIx6 NYPOcnVHOjFyNEi3PFU>
518A2  NV;nSFdkS2WubDDWbYFjcWyrdImgRZN{[Xl? MkjYNE4xOeLCk{Gw5qCK|ryP NYDYflJYPzJiaB?= MnH6bY5pcWKrdIOgZ4VtdCC4aXHibYxqfHliZH;z[UBl\XCnbnTlcpRtgQ>? M{fZbFIyODR6N{i1
Mel-Juso  MnrOSpVv[3Srb36gRZN{[Xl? Moj6NE4xODIkgKOx5qCK|ryP MlfsNlQhcA>? NWX4ZmZDe3WycILld5NmeyCyaH;zdIhwenmuYYTpc44hd2ZicHjvd5Bp[XSrZInsJIlvd3OrdH;sJFMuc2mwYYPlJIRwf26|dILlZY0hfGG{Z3X0dy=> M{KwcVIyODR6N{i1
518A2 NIj4fZdHfW6ldHnvckBCe3OjeR?= MnXlNE4xODIkgKOx5qCK|ryP NYf3dGluOjRiaB?= Mknld5VxeHKnc4Pld{BxcG:|cHjvdplt[XSrb36gc4YheGixc4DoZZRq\HmuIHnuc5NqfG:uIEOtb4lv[XOnIHTve45{fHKnYX2geIFz\2W2cx?= NWjROVRQOjFyNEi3PFU>
PC3  MVXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MWGyOIg> NES4Z2JIUTVywrC9JFExOCCwTR?= NHHCcGIzODV3MUC2NS=>
U87MG MUDGeY5kfGmxbjDBd5NigQ>? NFHae24xNjFvMTFOwG0> M2\3blI16oDLaNMg MV;EUXNQ NIXkO2pqdmirYnn0d{BRUTONLX3l[IlifGWmIIPp[45idGmwZx?= M{DrNFE6PjN|Nkiz
U138MG MmDWSpVv[3Srb36gRZN{[Xl? M{fBWVAvOS1zIN88US=> NUPGbGdkOjUkgJnoxsA> M{jl[WROW09? MkHabY5pcWKrdIOgVGk{Uy2vZXTpZZRm\CC|aXfuZYxqdmd? NUTnTZJ6OTl4M{O2PFM>
U118MG NFnhRYJHfW6ldHnvckBCe3OjeR?= MkfCNE4yNTFizszN Mkm1NlTjiImqwrC= M3TYNWROW09? MoC3bY5pcWKrdIOgVGk{Uy2vZXTpZZRm\CC|aXfuZYxqdmd? NYnJd5RZOTl4M{O2PFM>
U87MG MnLMS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXy5cJJxUUN3ME2wMlE1KM7:TR?= MWWxPVU5PDJ{Nx?=
IGROV-1 NYTBPXlpT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NF72RZdKSzVyPUCuNFYh|ryP NFHxZo4yQTV6NEKyOy=>
DETROIT562 MYTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHrKW4dKSzVyPUCuNVMh|ryP MkD3NVk2QDR{Mke=
PC3  NW\rTJZmT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MnKyTWM2OD1yLkGwJO69VQ>? NF\qeGMyQTV6NEKyOy=>
SKOV-3 M3vaOGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NF7RdGRKSzVyPUCuNVIh|ryP NEGweo8yQTV6NEKyOy=>
HUVEC M2j5OGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVTmcIk4UUN3ME2wMlA5KM7:TR?= MlnXNVk2QDR{Mke=
UCH-1  Mnf3SpVv[3Srb36gRZN{[Xl? NELydlYxNTVizszN NF;0OZVqdmirYnn0d{B1cGVicHjvd5Bpd3K7bHH0bY9vKG:oIHLveIghSUuWIHHu[EBuXE:UIHnuJIEh\G:|ZT3k[ZBmdmSnboSgcYFvdmW{ NGDzfJgyQTV{OES0NS=>
UCH-1  MkPUS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M{D2dlAvODFvMUCg{txO M3jiUFYh\A>? MmHkbY5pcWKrdIOgdJJwdGmoZYLheIlwdiCmb4PlJIRmeGWwZHXueIx6 NIraR2oyQTV{OES0NS=>
UCH-1  NWrZN2pISXCxcITvd4l{KEG|c3H5 MlvRNE4yNTFyIN88US=> NWTQZol[OjRiaB?= MlywSG1UVw>? NGDDXGVqdmS3Y3XzJIFxd3C2b4Ppdy=> MkSzNVk2Ojh2NEG=

多くの細胞株試験データを見る場合、クリックしてください

体内試験 When tumors reach 50-100 mm3, animals are randomized and treated with vehicle or PI-103. PI-103 exhibits significant activity, decreasing average tumor size by 4-fold after 18 days. [2] Mice treated with PI-103 have no obvious signs of toxicity premorbidly (based on body weight, food and water intake, activity, and general exam) or at necropsy. Treated tumors display decreased levels of phosphorylated Akt and S6, consistent with blockade of p110α and mTOR. PI-103 treatment is cytostatic to glioma xenografts. [2]

お薦めの試験操作(参考用のみ)

キナーゼ試験:[3]
+ 展開

Enzyme Assays:

Phosphatidylinositide 3-kinase inhibitory activity was determined using a scintillation proximity assay in the presence of 1 μmol/L ATP. Inhibition of mTOR protein kinase was determined using a TR-FRET-based LanthaScreen method from Invitrogen. Compounds were assayed at a maximum concentration of 10 μmol/L in the presence of 1 μmol/L ATP, and IC50 values were determined using GraphPad Prism software.
細胞試験: [2]
+ 展開
  • 細胞株: U87MG cells
  • 濃度: 0.5 μM
  • 反応時間: 24 hours
  • 実験の流れ: U87MG cells are treated with PI-103 for 24 hours. Cell death is quantified by colorimetric determination of LDH activity using a cytotoxicity detection kit. Percentage of cell death (mean of three 12-well plates per experimental point) is calculated [(experimental value- low control)/(high control -low control) × 100], where the low-control cells are DMSO treated and high-control cells are Triton treated (1% Triton X-100, 30 min, 37 °
    (参考用のみ)
動物試験:[2]
+ 展開
  • 動物モデル: 6- to 12-week-old Balbc nu/nu mice bearing U87MG:ΔEGFR cells
  • 製剤: 50% DMSO
  • 投薬量: 5 mg/kg
  • 投与方法: Administered via i.p.
    (参考用のみ)

溶解度 (25°C)

体外 DMSO 24 mg/mL (68.89 mM)
Water Insoluble
Ethanol Insoluble
体内 順序で溶剤を入れること:
1% DMSO+30% polyethylene glycol+1% Tween 80
30 mg/mL

* 溶解度検測はSelleck技術部門によって行いますので、文献より提供された溶解度と差異がある可能性がありますが、生産工芸と不同ロット(lot)で起きる正常な現象ですから、ご安心ください。

化学情報

分子量 348.36
化学式

C19H16N4O3

CAS No. 371935-74-9
保管
別名 N/A

便利ツール

モル濃度計算器

モル濃度計算器

解決のために必要とされるマス、ボリュームまたは濃度を計算してください。

マス (g) = 濃度 (mol/L) x ボリューム (L) x 分子量 (g/mol)

モル濃度計算器方程式

  • マス
    濃度
    ボリューム
    分子量

*貯蔵液を準備するとき、常に、オンであるとわかる製品のバッチに特有の分子量を使って、を通してラベルとMSDS/COA(製品ページで利用可能な)。

希釈計算器

希釈計算器

貯蔵液を準備することを要求される希釈剤を計算してください. セレック希釈計算器は、以下の方程式に基づきます:

開始濃度 x 開始体積 = 最終濃度 x 最終体積

希釈の計算式

この方程式は、一般に略語を使われます:C1V1 = C2V2 ( 輸入 輸出 )

  • C1
    V1
    C2
    V2

常に貯蔵液を準備するとき、小びんラベルとMSDS/COA(オンラインで利用できる)で見つかる製品のバッチに特有の分子量を使ってください。

連続希釈計算器方程式

  • 連続希釈剤

  • 計算結果

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
分子量計算器

分子量计算器

そのモル質量と元素組成を計算するために、合成物の化学式を入力してください:

総分子量:g/mol

チップス: 化学式は大文字と小文字の区別ができます。C10H16N2O2 c10h16n2o2

モル濃度計算器

マス 濃度 ボリューム 分子量

技術サポート

ストックの作り方、阻害剤の保管する方法、細胞実験や動物実験に注意すべきな点を全部含めており、製品を取扱う時よくあった質問に対して取扱説明書でお答えいたします。

Handling Instructions

他の質問がある場合は、お気軽くお問合せください。

  • * 必須

PI3K信号経路図

PI3K Inhibitors with Unique Features

相関PI3K製品

Tags: PI-103を買う | PI-103 ic50 | PI-103供給者 | PI-103を購入する | PI-103費用 | PI-103生産者 | オーダーPI-103 | PI-103化学構造 | PI-103分子量 | PI-103代理店
×
細胞株 試験類型 濃度 培養時間 溶剤類型 活性叙述 PMID